Vyvanse (Lisdexamfetamine): Complete Drug-Drug Interaction Profile

How Vyvanse Works: The Prodrug Mechanism That Shapes Its Interactions

Lisdexamfetamine is an inactive prodrug. It consists of the amino acid L-lysine covalently bonded to d-amphetamine, and this bond must be cleaved by peptidase enzymes in red blood cells before the active drug is released [1]. This hydrolysis step is capacity-limited and occurs independent of hepatic cytochrome P450 enzymes, which means the activation of lisdexamfetamine itself is not vulnerable to CYP-based drug interactions.

The released d-amphetamine, however, follows standard amphetamine pharmacokinetics. It increases synaptic concentrations of norepinephrine and dopamine by reversing monoamine transporters (DAT and NET), inhibiting vesicular monoamine transporter 2 (VMAT2), and weakly inhibiting monoamine oxidase [2]. d-Amphetamine is partially metabolized by CYP2D6 to inactive 4-hydroxyamphetamine and undergoes pH-dependent renal excretion [3]. These downstream pathways are where the clinically meaningful interactions occur. Wigal et al. demonstrated sustained ADHD symptom reduction over 12 to 13 hours with lisdexamfetamine, confirming the prolonged pharmacokinetic tail that makes interaction timing relevant throughout the day [4].

Absolute Contraindication: MAOIs

Do not prescribe Vyvanse to any patient who has taken a monoamine oxidase inhibitor within the preceding 14 days. This is not a dose-adjustment scenario. It is a hard stop.

MAOIs (phenelzine, tranylcypromine, isocarboxazid, selegiline transdermal at doses above 6 mg/24 hr) block the degradation of norepinephrine, dopamine, and serotonin. Adding amphetamine on top of MAO inhibition causes massive monoamine accumulation. The result can be hypertensive crisis, hyperthermia, seizures, and death [5]. The FDA label for lisdexamfetamine states: "Do not administer VYVANSE during or within 14 days following the administration of monoamine oxidase inhibitors" [1]. Linezolid (an antibiotic with weak MAOI activity) and intravenous methylene blue carry the same 14-day washout requirement per FDA safety communication [6]. A prescriber who needs to start Vyvanse in a patient on selegiline patch 6 mg/24 hr should consult psychiatry, as low-dose transdermal selegiline may pose lower (but not zero) risk.

Serotonergic Agents: SSRIs, SNRIs, and Serotonin Syndrome Risk

Combining Vyvanse with serotonergic medications increases the risk of serotonin syndrome, a potentially life-threatening condition marked by agitation, hyperthermia, clonus, and autonomic instability.

d-Amphetamine promotes serotonin release through SERT reversal [2]. When this mechanism overlaps with drugs that block serotonin reuptake (SSRIs like sertraline, fluoxetine, escitalopram; SNRIs like venlafaxine, duloxetine) or increase serotonin synthesis/release (triptans, tramadol, St. John's Wort), the additive serotonergic load can cross a toxic threshold. The Diagnostic and Statistical Manual does not define serotonin syndrome; clinicians use the Hunter Serotonin Toxicity Criteria, which require the presence of a serotonergic agent plus specific clinical findings (spontaneous clonus, inducible clonus with agitation, ocular clonus with diaphoresis) [7].

In practice, millions of patients take a stimulant alongside an SSRI. The combination is not contraindicated. But prescribers should start low, titrate slowly, and instruct patients to report muscle twitching, fever, or confusion immediately. Fluoxetine and paroxetine deserve extra caution because they are potent CYP2D6 inhibitors, adding a pharmacokinetic interaction on top of the pharmacodynamic one (see CYP2D6 section below) [8].

CYP2D6 Inhibitors: A Pharmacokinetic Amplifier

Strong CYP2D6 inhibitors raise circulating d-amphetamine levels by blocking its oxidative metabolism, which may intensify both therapeutic and adverse effects.

d-Amphetamine undergoes CYP2D6-mediated 4-hydroxylation as one of its elimination pathways [3]. When a strong CYP2D6 inhibitor (fluoxetine, paroxetine, bupropion, quinidine) is co-administered, the clearance of d-amphetamine slows. No large randomized trial has quantified the exact AUC increase for this specific pair, but extrapolation from amphetamine PK studies suggests a 20% to 40% increase in exposure is plausible in extensive metabolizers [9]. For patients who are CYP2D6 poor metabolizers (approximately 7% to 10% of Caucasians, per the Clinical Pharmacogenetics Implementation Consortium), this pathway is already nonfunctional, and adding an inhibitor has minimal additional effect [10].

Clinically, this means: if a patient on stable Vyvanse 50 mg begins paroxetine 20 mg, monitor for increased heart rate, insomnia, appetite suppression, and anxiety over the following 2 to 4 weeks. A Vyvanse dose reduction of 10 to 20 mg may be warranted. Conversely, discontinuing a CYP2D6 inhibitor in a patient on Vyvanse could reduce amphetamine levels and blunt ADHD symptom control.

Tricyclic Antidepressants

Tricyclics (desipramine, nortriptyline, imipramine) interact with Vyvanse through two distinct pathways: pharmacodynamic noradrenergic potentiation and pharmacokinetic CYP2D6 competition.

Both amphetamine and tricyclics increase synaptic norepinephrine. The combination amplifies cardiovascular effects, specifically elevations in heart rate and blood pressure [11]. Desipramine serum levels may also rise because amphetamine and desipramine share CYP2D6-mediated metabolism. A case series published in the Journal of Clinical Psychopharmacology documented a 30% mean increase in desipramine levels when d-amphetamine was co-administered [11]. Baseline and follow-up ECGs are recommended when combining these agents, with particular attention to QTc interval. Avoid the combination if the patient has a history of cardiac arrhythmia.

Antihypertensives: Pharmacodynamic Opposition

Amphetamines raise blood pressure through peripheral norepinephrine release. This directly opposes the mechanism of antihypertensive drugs.

A meta-analysis of stimulant trials in adults with ADHD found mean systolic blood pressure increases of 2 to 4 mmHg and heart rate increases of 3 to 6 bpm [12]. In patients already on antihypertensives (lisinopril, amlodipine, metoprolol, losartan), these stimulant-driven increases may partially negate pharmacotherapy. The interaction is pharmacodynamic, not pharmacokinetic. No dose conversion formula exists. Instead, the approach is empirical: check blood pressure 2 to 4 weeks after starting or titrating Vyvanse. Adjust the antihypertensive dose upward if readings exceed target. Beta-blockers (propranolol, labetalol) require additional caution. Unopposed alpha-adrenergic stimulation from amphetamine combined with beta-blockade could theoretically worsen hypertension, though this concern is extrapolated primarily from cocaine/beta-blocker literature and is debated in the amphetamine context [13].

Alpha-2 agonists (clonidine, guanfacine) present a different picture. These are commonly co-prescribed with stimulants for ADHD, and the combination has been studied in pediatric trials. The CADDRA guidelines consider this a standard augmentation strategy, but clinicians should monitor for hypotension, bradycardia, and sedation, particularly during dose titration [14].

Urinary pH Modifiers: The Renal Excretion Variable

d-Amphetamine is a weak base with a pKa of approximately 9.9. Its renal excretion is highly sensitive to urine pH.

In acidic urine (pH <6), amphetamine is ionized and trapped in the renal tubule, accelerating clearance. In alkaline urine (pH >7.5), amphetamine remains un-ionized and is reabsorbed, prolonging its half-life [3]. This is not a minor effect. Studies from the 1960s and 1970s demonstrated that alkalinizing urine with sodium bicarbonate could double the half-life of amphetamine, while acidification with ammonium chloride shortened it by 50% or more [15].

Drugs and substances that alkalinize urine (sodium bicarbonate, acetazolamide, citrate-based antacids) can increase Vyvanse effect and duration. Drugs that acidify urine (methenamine, high-dose ascorbic acid, ammonium chloride) can reduce it. Patients who self-medicate with large daily doses of vitamin C (more than 1 to 000 mg) may notice reduced Vyvanse efficacy. Ask about supplement use during medication reconciliation.

Proton Pump Inhibitors and GI pH Modifiers

Proton pump inhibitors (omeprazole, esomeprazole, pantoprazole) raise gastric pH but do not meaningfully alter the activation of lisdexamfetamine, which occurs in red blood cells rather than in the GI lumen [1].

However, an indirect interaction exists. PPIs can raise urinary pH slightly (by approximately 0.3 to 0.5 units in some individuals), which could modestly slow renal amphetamine clearance [16]. H2 blockers (famotidine, ranitidine) have a smaller effect on gastric pH and are unlikely to produce a clinically meaningful interaction. Antacids containing magnesium hydroxide or calcium carbonate can transiently raise gastric pH and, if taken in large amounts, may slightly alter absorption kinetics. The practical recommendation: standard PPI doses do not require Vyvanse dose adjustment, but if a patient reports new-onset insomnia or jitteriness after starting a PPI, consider the urinary pH mechanism.

Sympathomimetics and Vasoconstrictors

Co-administering Vyvanse with other sympathomimetic agents produces additive cardiovascular and CNS stimulation.

Pseudoephedrine, phenylephrine (oral decongestants), and prescription vasoconstrictors (midodrine) all increase peripheral norepinephrine signaling. The combination with amphetamine raises the risk of tachycardia, hypertension, and cardiac arrhythmia [5]. Patients should be counseled to avoid OTC cold medications containing pseudoephedrine or phenylephrine while on Vyvanse. Caffeine, while not a classical sympathomimetic, amplifies the CNS-stimulant effects of amphetamine, and the FDA label notes the additive potential [1]. Patients consuming more than 200 mg of caffeine daily (roughly two standard cups of coffee) while on Vyvanse should be assessed for anxiety, palpitations, and insomnia.

Anticonvulsants and Mood Stabilizers

Phenobarbital, phenytoin, and ethosuximide may have delayed GI absorption when co-administered with amphetamines, per the FDA label [1].

Amphetamines can also lower the seizure threshold. For patients on valproate, lamotrigine, or levetiracetam for epilepsy, the addition of Vyvanse requires a risk-benefit discussion. A retrospective cohort study found no statistically significant increase in seizure frequency among epilepsy patients prescribed stimulants, but the sample size was small (N=107) and confidence intervals were wide [17]. Lithium may blunt the CNS-stimulant effects of amphetamines through its antidopaminergic activity, though this interaction is based on limited evidence from case reports rather than controlled trials [5].

Anesthetic Agents

Patients on Vyvanse who require surgery should inform their anesthesiologist. Halogenated anesthetics (halothane, sevoflurane) can sensitize the myocardium to catecholamines, and the added norepinephrine load from amphetamines increases the risk of intraoperative arrhythmia [1].

The standard recommendation from the American Society of Anesthesiologists is to continue chronic stimulant therapy on the day of surgery if abrupt cessation would produce rebound symptoms, but to communicate the medication status to the anesthesia team [18]. Withholding Vyvanse on the morning of surgery is a reasonable alternative in elective cases. The decision rests with the anesthesiologist, not the prescribing clinician acting alone.

Cannabinoids and Alcohol

Alcohol does not alter the rate-limited hydrolysis of lisdexamfetamine, but it does impair judgment and may mask the subjective perception of amphetamine intoxication, increasing overdose risk [1].

Cannabis (THC) combined with amphetamine produces additive tachycardia. A crossover study in healthy volunteers (N=36) found that the combination of d-amphetamine 20 mg and vaporized THC increased heart rate by a mean of 28 bpm compared with 15 bpm for amphetamine alone [19]. Patients using cannabis should be monitored for cardiovascular symptoms. CBD, as a moderate CYP2D6 inhibitor, could modestly raise d-amphetamine levels, though this interaction has not been studied with lisdexamfetamine specifically.

Interaction Summary by Risk Tier

Contraindicated (do not co-prescribe): MAOIs (including linezolid, IV methylene blue) within 14 days.

High risk (requires active monitoring and possible dose adjustment): SSRIs/SNRIs (serotonin syndrome risk), tricyclic antidepressants (noradrenergic potentiation plus TCA level increases), strong CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion, quinidine).

Moderate risk (monitor clinically): Antihypertensives (pharmacodynamic opposition), urinary alkalinizers (prolonged amphetamine effect), sympathomimetics/vasoconstrictors (additive cardiovascular load), anticonvulsants (seizure threshold), halogenated anesthetics (arrhythmia).

Low risk (counsel patient): PPIs, caffeine, alcohol, OTC antacids, high-dose vitamin C.

The first follow-up visit after adding or removing any interacting medication should include blood pressure, heart rate, and a targeted review of stimulant side effects (appetite, sleep latency, mood) within 2 to 4 weeks of the change [14].